Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resveratrol, Alpha Lipoic Acid, and Superoxide Dismutase for Diabetic Neuropathy
NCT06131918Phase 2Completed
- Sponsor
- Khyber Medical University
- Start
- Jan 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of resveratrol, alpha-lipoic acid and superoxide dismutase in diabetic peripheral neuropathy (DPN) (4 arms), sponsored by Khyber Medical University. Primary endpoints: Change in nerve conduction latency at 4 months, Change in nerve conduction velocity at 4 months and 2 more. Started Jan 2023; status: completed.
02
Drugs
resveratrolalpha-lipoic acidsuperoxide dismutase
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT06131918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06131918.